Intra-articular glucocorticoid injections decrease the number of steroid hormone receptor positive cells in synovial tissue of patients with persistent knee arthritis by van der Goes, M. C. et al.
Basic and translational research
1552 Ann Rheum Dis 2012;71:1552–1558. doi:10.1136/annrheumdis-2011-201019. 
1Department of Rheumatology & 
Clinical Immunology, University 
Medical Center Utrecht, 
Utrecht, The Netherlands
2Laboratory of Experimental 
Rheumatology and 
Neuroendocrino-Immunology, 
Department of Internal 
Medicine I, University Hospital 
Regensburg, Regensburg, 
Germany




Marlies van der Goes, 
Department of Rheumatology & 
Clinical Immunology (F02.127), 
University Medical Center 
Utrecht, PO Box 85500, 3508 
GA Utrecht, The Netherlands; 
m.c.vandergoes@umcutrecht.nl
Received 4 November 2011
Accepted 26 February 2012
ABSTRACT
Objectives To explore changes in the number of steroid 
hormone receptor positive cells in synovial tissue (ST) 
after intra-articular glucocorticoid injection, to correlate 
these changes with changes in clinical variables, and 
to evaluate whether the number of steroid hormone 
receptor positive cells predicted the clinical response to 
glucocorticoid injection.
Methods Fourteen patients with persistent knee 
arthritis despite at least two previous injections in an 
outpatient setting received an intra-articular injection 
with glucocorticoids, followed by 3 days of admission 
with bed rest. Clinical effi cacy was assessed at 6 and 
12 weeks. ST biopsies were performed 2 weeks before 
and 12 weeks after the injection. The presence of 
different cell types (T cells, macrophages, fi broblast-like 
synoviocytes) and numbers of glucocorticoid, androgen 
and oestrogen α and β receptor positive cells were 
evaluated by histochemistry.
Results Patients showed, despite previous failures, good 
clinical response to glucocorticoid injection, with signifi cant 
improvement in erythrocyte sedimentation rate, visual 
analogue scale (VAS) for pain, and joint disability score. 
The number of steroid hormone receptor positive cells 
decreased markedly (p<0.05 for all four receptors). The 
decrease in oestrogen receptor α positive cells correlated 
signifi cantly with the improvement in VAS for pain and joint 
disability score. The number of glucocorticoid, androgen 
and oestrogen α and β receptor positive cells before 
injection did not predict the effect of treatment.
Conclusions Intra-articular glucocorticoid injections 
followed by bed rest for persistent arthritis are clinically 
effective and signifi cantly decrease the number of steroid 
hormone receptor positive cells in ST. The relevance of 
the latter needs further study.
INTRODUCTION
Steroid hormones of the adrenal and gonadal 
glands, such as glucocorticoids, androgens and 
oestrogens, are important in the neuroendocrine 
immune system and are involved in the immuno-
logical imbalance in several autoimmune diseas-
es.1 2 Systemically as well as locally administered 
glucocorticoids clearly exhibit anti-inﬂ ammatory 
actions.3–6 In rheumatoid arthritis (RA), systemic 
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glucocorticoids are capable of slowing down the 
progression of joint destruction.7–11 It was recently 
demonstrated that the inclusion of 10 mg predni-
sone from the start of therapy in a methotrexate-
based tightly controlled treatment strategy resulted 
in fewer radiographic erosions without increasing 
toxicity, and decreased the need for treatment with 
biological agents.12 The effects of androgens on RA 
disease activity are limited.13–15 The role of oestro-
gens in RA and autoimmune diseases is more difﬁ cult 
to deﬁ ne,16 and may be inﬂ uenced by the presence 
of its receptors (oestrogen receptor α and β (ERα 
and ERβ)), as preponderance of one ER subtype over 
another may inﬂ uence the effects of oestrogens.17
Previous research has shown the presence of 
steroid hormone receptors in different cells in the 
synovial tissue (ST) as well as in peripheral blood 
mononuclear cells of patients with RA.18–24 Steroid 
hormone receptors in ST are localised in inﬂ amma-
tory lymphoid cells and synoviocytes.23 However, 
the effects of intra-articular glucocorticoid injec-
tions on the presence of steroid hormone receptor 
positive cells have thus far not been described.
In rheumatic diseases, systemically administered 
glucocorticoids inhibit expression of the glucocor-
ticoid receptor (GR) on peripheral blood mononu-
clear cells in a dose-dependent way.25 However, 
previous studies have not demonstrated a direct 
relation between peripheral blood mononuclear cell 
GR expression and efﬁ cacy of oral glucocorticoid 
treatment.26 This does not exclude the possibility 
that there is a correlation at the local level between 
the expression of this and other steroid recep-
tors in ST cells and the response to intra-articular 
glucocorticoid treatment. It has been shown that 
intra-articularly injected glucocorticoids decrease 
serum levels of dehydroepiandrosterone sulphate, 
testosterone and oestradiol.27 However, no data 
are available on the local effect of intra-articular 
glucocorticoids on expression of different steroid 
hormone receptors in ST.
Therefore, we performed an explorative study in 
which we aimed to:
explore whether the numbers of GR, androgen 1. 
receptor (AR), ERα and ERβ positive cells in 
ST change after intra-articular glucocorticoid 
injection in persistent knee arthritis;
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determine whether changes in numbers of these positive 2. 
cells correlate with improvement in clinical variables;
identify whether the number of steroid hormone receptor 3. 




Fourteen patients with RA or undifferentiated arthritis (UA) and 
with persistent knee arthritis who gave written informed con-
sent to have a serial ST biopsy were included at four rheumatol-
ogy clinics in The Netherlands. The patient characteristics are 
given in table 1. The requirement for participation was persis-
tent knee arthritis despite at least two intra-articular glucocorti-
coid injections in an outpatient setting, which was ongoing for 
at least 4 weeks after the last glucocorticoid injection. The study 
protocol was approved by the ethics committee of the partici-
pating institutions and conducted according to the Declaration 
of Helsinki.
Treatment
Patients received intra-articular treatment with either 20 mg 
triamcinolone hexacetonide (n=9) or 40 mg triamcinolone ace-
tonide (Kenacort; Bristol-Meyers Squibb BV , The Netherlands; 
n=5), after aspiration of the synovial ﬂ uid. Availability deter-
mined the use of two different glucocorticoid preparations, and 
the dosage adjustment was based on pharmacokinetic reports.28 
There were no signiﬁ cant differences between the two prepara-
tions in (change of) number of steroid hormone positive cells (p 
values all >0.1), and the direction of change was similar for both 
preparations. Therefore they were considered clinically equipo-
tent, and results are presented for both glucocorticoids together. 
Treatment was followed by immobilisation of the knee with a 
brace and 72 h bed rest at the clinic, because bed rest improved 
outcomes in an earlier study.29
Clinical assessment
At baseline and at 6 and 12 weeks after intra-articular gluco-
corticoid injection, clinical assessments were performed by one 
investigator. Pain in the joint was scored by the patient on a 
visual analogue scale (VAS), ranging from 0 (no pain) to 100 mm 
(maximal pain). Functional disability of the treated joint was 
scored on a ﬁ ve-point Likert scale (1=complete immobilisation, 
5=no symptoms). The acute phase reactants, erythrocyte sedi-
mentation rate (ESR) and C-reactive protein (CRP), were also 
measured.
Biopsy procedure and tissue preparation
Two weeks before and 12 weeks after treatment, ST biopsy 
samples were taken using a blind procedure from the suprapa-
tellar pouch and medial parapatellar gutter, after intra-articular 
anaesthesia with lidocaine. No prophylactic antibiotics were 
administered, and no aspiration of synovial ﬂ uid was performed 
at the time of biopsy. The biopsy procedures were performed 
by one investigator with straight arthroforce III biopsy for-
ceps (Storz, Tuttlingen, Germany) with a diameter of 2.3 mm, 
through a biopsy canule (Storz) with a diameter of 3.2 mm and 
length of 7 cm. Ten pieces of ST were snap-frozen en block in 
Tissue Tek OCT (Miles, Elkhart, Indiana, USA) by immersion in 
methylbutane (−70°C) immediately after retrieval and stored in 
liquid nitrogen.30
Sections (5 μm) of the combined biopsy pieces were cut in a 
cryostat and mounted on glass slides (Star Frost adhesive slides; 
Knittelgläser, Braunschweig, Germany). The slides were air-
dried overnight and sealed by wrapping in tin foil to store at 
−70°C until histochemical analyses. In addition, ﬁ ve pieces of 
ST were ﬁ xed in formalin, embedded in parafﬁ n, and cut into 
5 μm sections of the combined biopsy pieces for steroid hor-
mone receptor staining.
Immunohistochemistry
Serial frozen sections were stained with the following mouse 
monoclonal antibodies: anti-CD3 (SK7; Becton-Dickinson, San 
Jose, California, USA) to detect T lymphocytes, anti-CD68 
(ERM11; Dako, Glostrup, Denmark) to detect macrophages, 
and anti-CD55 (clone 67; Serotec, Oxford, UK) to detect 
ﬁ broblast-like synoviocytes. Staining was centralised and per-
formed according to a three-step immunoperoxidase method, 
as described previously,30 with the material of all patients pro-
cessed at the same time.
The parafﬁ n sections were deparafﬁ nised in xylene and rehy-
drated in a descending ethanol concentration series. Procedures 
were followed as described previously.18 Slides were placed 
in citrate buffer (S2369; Dako) and heated for 40 min in a 
water bath at 90°C. They were then washed in Tris buffer (pH 
7.6), trypsin-digested for 20 min at 37°C (trypsin 10x, PAA, 
Pasching, Austria), and washed again in Tris buffer. After that, 
they were incubated for 45 min in blocking solution consist-
ing of 10% bovine serum albumin (Sigma, Zwijndrecht, The 
Netherlands), 10% fetal calf serum (PAN Biotech, Aidenbach, 
Germany) and 10% goat serum (Sigma) and washed in Tris 
buffer. Antibodies to GR (35473; Menarini, Florence, Italy), AR 
(DLN-09477; Dianova, Hamburg, Germany), ERα (MA1-310; 
Dianova) and ERβ (ab288; Abcam, Cambridge, Massachusetts, 
USA) were applied at pretested dilutions overnight at room 
temperature. As a negative control, sections were incubated 
without the primary antibody. After a wash in Tris buffer, 
the secondary antibody (D0486; Dako) was applied for 1 h at 
room temperature. After a further wash in Tris, these slides 
were incubated with the chromogen, 5-bromo-4-chloro-3-
indoyl phosphate/nitroblue tetrazolium, and levamisole was 
added to block endogenous alkaline phosphatase (K0598 and 
X3021; Dako).
Table 1 Characteristics of patients
All (n=14) RA (n=8) UA (n=6)
Female/male (n)  6:8  3:5  3:3
Age (years) 53±15 59±13 44±14
Disease duration (years)  7 (2–11)  9 (2–28)  5 (1–9)
Erosive joint disease (n)  5  5  0
Duration of knee arthritis (months) 36±30 33±24 40±38
Number of injections during 
past year
 3±2  3±2  2±1
Generic glucocorticoid
 Triamcinolone hexacetonide (n)  9  3  6
 Triamcinolone acetonide (n)  5  5  0
Current therapy
 NSAIDs (n)  9  6  3
 DMARDs (n)  9  8  1
 Oral glucocorticoids (n)  5  4  1
ESR (mm/h) 34 (11–76) 73 (26–88) 13 (7–32)
CRP (mg/l) 16 (5–95) 68 (10–124)  7 (4–12)
Data represent mean±SD, or median (IQR) when not normally distributed. A signifi cant 
difference between the RA and UA group was found only for DMARD use (p=0.008) 
and ESR (p=0.017).
CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, 
erythrocyte sedimentation rate; NSAID, non-steroidal anti-infl ammatory drug; RA, 
rheumatoid arthritis; UA, undifferentiated arthritis.
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Microscopic analysis
Sections stained for CD markers were randomly analysed by one 
observer blinded to the time point using digital image analysis, as 
previously described.31 Of the sections stained for steroid hormone 
receptors, representative high-power ﬁ elds (200×) were examined 
independently by two observers (for an example, see ﬁ gure 1). 
The observers were blinded to all clinical data and the time point. 
Numbers of receptor positive cells were averaged from nine selected 
high-power ﬁ elds. The cell counts were expressed per mm2.
Data analysis
Baseline characteristics of patients with RA and UA were 
tested for differences with independent samples T tests or 
Mann–Whitney U tests, where appropriate, and differences in 
categorical data with Pearson χ2 tests with continuity correc-
tions. Means of the histology scores of the two investigators 
were used. Since most variables were not normally distributed, 
non-parametric statistics was applied. For comparison of clini-
cal variables and histological scores before and after injection, 
the Wilcoxon signed ranks test was used, and, for comparisons 
between groups, the Mann–Whitney U test was applied. To 
analyse relations between clinical outcome, receptor expres-
sion and CD markers, Spearman’s correlations were performed. 
Prediction was tested with linear regression analyses (with 
absolute values of, and change in, ESR, CRP, VAS for pain and 
disability scores at 6 and 12 weeks after treatment as dependent 
variables). For all analyses, p values of <0.05 were considered to 
be signiﬁ cant. Because of the explorative nature of this study, 
Bonferroni adjustment was not applied. Analyses were per-
formed with PASW V.18.0 (SPSS, Chicago, Illinois, USA).
RESULTS
Clinical effect
In patients with persistent knee arthritis despite previous injec-
tions, intra-articular glucocorticoid injections appeared to be 
effective, albeit temporarily (ﬁ gure 2). A signiﬁ cant improve-
ment in ESR, disability score and VAS pain score was observed 
at 6 weeks, which had partially faded after 12 weeks.
Figure 1 Synovial tissue stained for androgen receptor positive cells. These fi gures are examples of one of the stains used for steroid hormone 
receptors. An overview of the tissue is shown on the left (100×), with a more detailed view on the right (200×). The dark cells (some are indicated 
by arrows) are positive for androgen receptors.
Figure 2 Clinical scores before versus 6 and 12 weeks after glucocorticoid treatment. The measurements before and 6 and 12 weeks after treatment 
were complete for all patients, except for two missing ESR and CRP values at 6 and 12 weeks. Joint disability scores range from 1 (complete 
immobilisation) to 5 (no symptoms), and thus an increase in this score refl ects improvement. VAS pain scores range from 0 to 100 mm, and thus a 
decrease in this score refl ects improvement. Clinical scores after 6 versus 12 weeks are all not signifi cant. CRP, C-reactive protein; ESR, erythrocyte 
sedimentation rate, VAS pain, visual analogue scale for pain of the treated joint.
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Effect of glucocorticoids on the presence of steroid hormone 
receptor positive cells
The number of steroid hormone receptor positive cells decreased 
signiﬁ cantly after intra-articular glucocorticoid injection for 
all four receptors tested (ﬁ gure 3A). Decreases were similar 
for patients with RA and UA, and independent of the use of 
disease-modifying antirheumatic drugs or non-steroidal anti-
inﬂ ammatory drugs (data not shown). Although changes in num-
bers of steroid hormone receptor positive cells were smaller in 
the group of ﬁ ve patients using oral glucocorticoid medication, 
the directions of the effects were uniform (data not shown). The 
decrease in steroid hormone receptor positive cells was similar 
in men and women, except for the decrease in ERα positive cells, 
which was more pronounced in women than men (p=0.03).The 
inter-relationship for changes in the different steroid hormone 
receptors was examined, and a weak correlation was found for 
most of them (Spearman correlation coefﬁ cients of 0.13–0.44, 
not signiﬁ cant). For the change in the two subtypes of ERs, a 
strong association was found (Spearman correlation coefﬁ cient 
0.72, p=0.004; ﬁ gure 3B).
Steroid hormone receptors and ST infl ammation
Several markers of synovial inﬁ ltration were tested (ﬁ gure 4). 
The number of T cells (CD3 positive cells) decreased signiﬁ cantly 
(p=0.01). Other cell types such as macrophages (CD68 positive 
cells) in the lining and sublining and ﬁ broblast-like synoviocytes 
(CD55 positive cells) did not show a clear change. Changes in 
synovial inﬁ ltration of the different cell types did not correlate 
with changes in numbers of steroid hormone receptor positive 
cells (data not shown).
Steroid hormone receptors and clinical effi cacy
Decreases in the number of GR, AR and ERβ positive cells were 
not associated with change in any clinical variable (ESR, CRP, 
VAS for pain, disability score). The decrease in number of ERα 
positive cells on the other hand correlated with an improvement 
in VAS for pain and joint disability at 6 weeks after glucocorticoid 
injection (Spearman correlation coefﬁ cient 0.65, p=0.02, and 
Spearman correlation coefﬁ cient −0.59, p=0.03; ﬁ gure 5). These 
correlations had disappeared at 12 weeks after treatment (data 
not shown), as the clinical effect also faded away.
Prediction
The number of GR, AR, ERα or ERβ positive cells in ST before 
treatment did not predict the clinical response to intra-articular 
glucocorticoid injections (no signiﬁ cant β of receptor expression 
in linear regression analyses with clinical variables as dependent 
Figure 3 Number of steroid hormone receptor positive cells before and after glucocorticoid injection and coupling of change in ERα and ERβ positive 
cells. Steroid hormone receptors are expressed as the number of positive cells per mm2. The p values indicate signifi cant differences between values 
before treatment and 12 weeks after intra-articular glucocorticoid injection (A). Strong coupling of change in number of positive cells was found for 
the two types of ER (Spearman correlation coeffi cient 0.72, p=0.004; B). AR, androgen receptor; ER, oestrogen receptor; GR, glucocorticoid receptor.
Figure 4 Presence of different cell types in the synovial tissue before 
and after glucocorticoid injection. Measurements of infi ltration of 
different cell types in the synovial lining and sublining before and after 
intra-articular glucocorticoid injection were performed in 13 patients 
and are expressed as cell counts per mm2 (divided by two for the Mφ 
scores). The number of T cells decreased signifi cantly (p=0.01). Other 
cell types did not change signifi cantly. FLS, fi broblast-like synoviocytes 
(CD55); Mφ, macrophages (CD68); T cells, T lymphocytes (CD3).
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variables). The number of T cells, macrophages and ﬁ broblast-
like synoviocytes at baseline also did not correlate with clinical 
response to this therapy.
DISCUSSION
Intra-articular glucocorticoid injections for persistent arthritis 
appeared to be effective albeit temporarily, and signiﬁ cantly 
decreased the number of steroid hormone receptor positive 
cells and T cells in ST. None of the baseline ST characteristics 
predicted the clinical response to glucocorticoid injection. The 
decrease in ERα positive cells correlated with clinical improve-
ment. The relevance of this correlation and the decrease in the 
number of steroid hormone receptor positive cells in general 
need further study.
Previous work on changes in ST in RA showed a marked 
decrease in synovial macrophages after 2 weeks of oral gluco-
corticoid therapy32 and a decrease in T cells after intra-articular 
glucocorticoids.33 Despite the greater time span of 12 weeks, 
the decrease in T cells was conﬁ rmed in our study. This prob-
ably reﬂ ects a long-lasting decrease in proinﬂ ammatory activity, 
possibly enhanced by immobilisation of the joint after injection, 
and could therefore explain the accompanying clinical effective-
ness of the intra-articular glucocorticoid injection, despite previ-
ous injections without immobilisation.
The presence of steroid hormone receptor positive cells in 
ST has been conﬁ rmed in several studies.18–21 23 The number 
of positive cells found in this study matches ﬁ ndings in earlier 
studies.18 23 32 GRs are thought to be involved in many pro-
cesses by which increased expression of anti-inﬂ ammatory pro-
teins or decreased production of proinﬂ ammatory proteins can 
be achieved.34 However, the role of the other steroid hormone 
receptors is less clear. The effects of intra-articular glucocor-
ticoid injections on the presence of steroid hormone receptor 
positive cells have not been described before. In this explor-
ative study, we found a decrease in the number of positive cells 
for all steroid hormone receptors tested. Interestingly, we did 
not ﬁ nd a correlation between the downregulation of steroid 
hormone receptor positive cells and the change in T cells or 
macrophages. This indicates that the downregulation of ste-
roid hormone receptor positive cells cannot be fully explained 
by a decrease in proinﬂ ammatory cells such as T cells and 
macrophages.
Glucocorticoids are thought to work via genomic and non-
genomic mechanisms.34 Binding of glucocorticoids to their 
cytosolic receptors initiates the classical genomic pathway and 
will result in anti-inﬂ ammatory effects, which lead to (partial) 
relief of symptoms and improvement in clinical variables. This 
is exempliﬁ ed by the decrease in disability, pain and ESR in this 
study. Presuming that, similar to the level of ERα messenger 
RNA,21 the level of GR messenger RNA also depends on the 
degree of inﬂ ammation, downregulation of the GR positive 
cells after glucocorticoid injection may be a logical consequence. 
Downregulation of positive cells for both ERs and AR is more 
difﬁ cult to understand, but positive correlations between super-
fusate concentrations of interleukin-6 and interleukin-8 and 
numbers of positive cells for both ERs in ST have been found in 
patients with RA.18 This indicates that inﬂ ammatory factors may 
upregulate the expression of ERs, or vice versa. Androgens are 
considered to exert anti-inﬂ ammatory effects in RA, although 
therapeutic effects in clinical studies have been limited.13–15 35 In 
this case, downregulation of its receptor may have been caused 
by downregulation of the inﬂ ammatory process as a secondary 
phenomenon.
Based on our results, the downregulation of ERα positive 
cells was more pronounced in women and coincided with relief 
of pain and improvement in joint disability (ﬁ gure 5), whereas 
the downregulation of ERβ positive cells was not signiﬁ cantly 
associated with clinical response to glucocorticoid injection. The 
two subtypes of ERs are structurally related, but are encoded by 
different genes and are thought to mediate different effects.17 
Figure 5 Correlations between change in ERα positive cells and clinical scores. The decrease in ERα positive cells (x axis) correlated with an 
improvement in VAS for pain and joint disability score (y axis) at 6 weeks after glucocorticoid injection. (A) Percentage change in VAS for pain and 
change in number of ERα positive cells (Spearman correlation coeffi cient 0.65, p=0.02). The positive correlation coeffi cient indicates that a decrease 
in ERα positive cells correlates with a decrease in VAS for pain. (B) Percentage change in joint disability score, which correlates with the change in 
number of ERα positive cells (Spearman correlation coeffi cient −0.59, p=0.03). Joint disability scores ranged from 1 (complete immobilisation) 
to 5 (no symptoms). So, the negative correlation coeffi cient indicates that a decrease in ERα positive cells correlates with a decrease in disability. 
ER, oestrogen receptor; VAS, visual analogue scale.
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ERα and ERβ are both present in sensory nerve ﬁ bres.36 In ani-
mal studies, oestrogens increased the expression of substance 
P precursor37 38 and substance P receptors.39 Furthermore, 17β-
oestradiol acted directly on the sensory neuron by increasing 
neurite outgrowth in the absence of other exogenous growth 
factors.40 So, it seems that oestrogens can support neurogenic 
inﬂ ammation and sensitisation to painful stimuli via these 
mechanisms, and this is in line with the previously described 
lack of beneﬁ t from therapy with oestrogens in RA.16 Therefore, 
a decrease in ER positive cells may lead to a diminished pain-
inducing capacity of oestrogens. The coupling of the downregu-
lation of ERα positive cells and clinical outcome found in this 
study is certainly another indication of the involvement of ERs 
in the inﬂ ammatory process, as found for the coupling of inter-
leukin-6 levels and the number of positive cells of both ERs in 
an earlier study.18 However, the underlying mechanisms causing 
the downregulation of ERα positive cells are not easily clariﬁ ed 
and are probably also partially dependent on the immune stimu-
lus, cell types involved and timing in relation to the disease.17 
It has been shown that activation of the GR by glucocorticoids 
induced the expression and activity of oestrogen sulphotrans-
ferase, an enzyme important for the metabolic deactivation of 
oestrogens because sulphonated oestrogens fail to activate the 
oestrogen receptor.41 The inhibition of oestrogen signalling may 
have caused downregulation of its receptor and the clinical ben-
eﬁ t observed.
Our ﬁ ndings are based on data from microscopic analyses 
of immunohistochemical staining. With this technique, cells 
are stained for the presence of steroid hormone receptors and 
are either positive or negative. Of course, the results on cell 
counts are important in improving our knowledge of the role 
of these receptors and their link to clinical variables. However, 
the number of cells does not tell us anything about the amount 
of receptors within one cell or the effects of glucocorticoids on 
individual cell populations, and therefore further studies with 
different techniques would be of additional value.
In our explorative study, we found correlations between the 
decrease in number of ERα positive cells and clinical variables, 
but were not able to predict clinical response from pretreatment 
numbers of steroid hormone positive cells or the number of spe-
ciﬁ c cell populations. The small number of patients in this study 
and the inclusion of patients with different backgrounds (RA 
and UA) and with different oral treatments may have inﬂ uenced 
the results. Nevertheless, these factors did not appear to inﬂ u-
ence our exploration of the local effects, which was indicated 
by the uniform directions of change in receptor positive cells for 
the RA and UA groups and for the patients with and without 
oral glucocorticoids. Although results of larger patient groups 
are often considered more valuable, application of these results 
at the individual patient level can become less reliable.
In conclusion, we have shown that the number of steroid hor-
mone receptor positive cells are decreased after intra-articular 
glucocorticoid injection, and the decrease in ERα positive cells 
correlated with an improvement in clinical outcome, suggesting 
that steroid hormone receptor positive cells in ST during persis-
tent arthritis play a role in the regulation of inﬂ ammation and 
the response to intra-articular glucocorticoid injection.
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